skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment

Original Research

(1577) Views  (919) Full article downloads

Authors: William G North, Guohong Gao, Amy Jensen, et al

Published Date April 2010 Volume 2010:2 Pages 31 - 40
DOI: http://dx.doi.org/10.2147/CPAA.S6262

William G North1, Guohong Gao1, Amy Jensen1, Vincent A Memoli2, Jinlin Du1

1Departments of Physiology and 2Pathology, Dartmouth Medical School, Lebanon, NH, USA

Abstract: We previously showed that functional N-methyl-D-aspartate (NMDA) receptors are expressed by human neuroblastoma cells. In this study we demonstrate functional NMDAR1 and NMDAR2 receptors are expressed by small-cell lung cancer (SCLC) classical cell lines NCI H146, NCI H345, and DMS 53, by variant cell line NCI H82, and by most SCLC tumors, and that these receptors are important for the growth of human SCLC tumor xenografts in mice. Reverse transcription-polymerase chain reaction demonstrated mRNA for both receptors, with sequences identical to those for human mRNAs, are expressed in all four cell lines, and these generated proteins of the expected sizes 120 and 170 kDa. Cell viability tests showed cell growth was significantly (P < 0.0001) impaired by NMDAR1 antagonists MK-801 and memantine. Ifenprodil and Ro25-6981, NMDAR2B antagonists at the polyamine site, also significantly (P < 0.001) inhibited the growth/survival of these cells. Alternatively, the glycine-binding antagonist, L701, 324, increased viability to 140% and 120% in NCI H345 and NCI H82 cells after 48 hours of incubation. Immunohistochemistry of SCLC tumors with our polyclonal antibodies gave specific positive staining for the NMDAR1 receptor in 8 of 10 tissues examined. Small amounts of these same antibodies significantly reduced the growth of NCI-H345 cells up to 25% (P < 0.001). When NCI H345 cells were grown as tumor xenografts in mice, the growth of these tumors was reduced by 60% (P < 0.001) by treatments with MK-801 over five days. All of these data point to active NMDAR receptors possibly having an important influence on SCLC growth and survival.

Keywords: NMDA, receptors, small-cell lung cancer, inhibition, treatment








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pharmacologic agents for smoking cessation: A clinical review
Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer  treatment and/or higher doses?
Cosyntropin as a diagnostic agent in the screening of patients for adrenocortical insufficiency
Academic leadership searches: evolving best practices
Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
Zinc oxide nanoparticles as selective killers of proliferating cells
Differences in maintenance of mean blood glucose (BG) and their association with response to “recognizing hunger”
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University